SECOND QUARTER APRIL-JUNE
- The Group's net sales amounted to
SEK 386.1 (284.1) million, an increase of 36 percent. -
The Group's EBITDA was
SEK 86.6 (59.4) million, an increase of 46 percent. - The EBITDA margin was 22 (21) percent.
-
Profit after tax amounted to
SEK 46.8 (21.1) million. -
Earnings per share amounted to
SEK 3.2 (1.4). -
Cash flow from operating activities was
SEK 39.7 (24.4) million.
HALF-YEAR JANUARY-JUNE
- The Group's net sales amounted to
SEK 766.3 (546.9) million, an increase of 40 percent. -
The Group's EBITDA was
SEK 146.0 (115.6) million, an increase of 26 percent. EBITDA adjusted for items affecting comparability*) amounted to 161.4 million, an increase of 40 percent. - The EBITDA margin was 19 (21) percent (21 percent adjusted for items affecting comparability*)).
-
Profit after tax amounted to
SEK 71.6 (40.8) million. -
Earnings per share amounted to
SEK 4.8 (2.7). -
Cash flow from operating activities was
SEK 92.3 (80.7) million.
"Continued strong growth in the second quarter - EBITDA increased by 46 percent"
Second quarter
The Group delivered a strong second quarter with high sales growth, increased earnings and progress for both
Sales showed good growth in the second quarter and the Group's net sales increased by 36 percent, with strong organic growth continuing at around 13 percent.
The Specialty Pharma business area continued to perform very well with strong demand in all businesses. Sales growth for the registered pharmaceutical portfolio continued, and the increased share of sales coming from the registered pharmaceutical portfolio contributed to the business area's improved margin. Demand for unlicensed pharmaceuticals and contract manufacturing was also high, and during the quarter it was decided to make capacity-increasing investments in production. The prioritised business development work, aimed at broadening the company's portfolio and sales, continued.
The
The Group's EBITDA increased by 46 percent and the margin was 22 percent. The
Growth through acquisitions and active ownership
After the end of the quarter, the acquisitions of SurgiCube and Toul Meditech were announced, both of which provide solutions for ultra clean air in surgical environments during procedures such as eye and orthopaedic surgery. The solutions are cost-effective and contribute to flexibility, capacity and quality for both hospitals and smaller clinics. We see potential to grow the platform and expanding sales and distribution to more markets and segments. We are pleased to welcome these businesses to
In summary
The Group delivered a very strong second quarter with a favourable combination of organic and acquired growth. Changes in the economy are difficult to predict, but so far the Group's companies have experienced good demand and positive development.
This information is information that
For more information, contact
About
https://news.cision.com/medcap-ab/r/continued-strong-growth---ebitda-increased-by-46-percent,c3810713
https://mb.cision.com/Main/2678/3810713/2207969.pdf
https://news.cision.com/medcap-ab/i/bild-anders,c3202396
(c) 2023 Cision. All rights reserved., source